We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mr
Stephen
Potter
stephen.potter@iow.nhs.uk
Prof
S. Hasan
Arshad
S.H.Arshad@soton.ac.uk
Chronic lower respiratory diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Severe asthma causes a considerable health-economic burden at both the individual and societal levels, including disability, missed schooling and lost work days. The growing realisation that severe asthma is not one condition but composed of numerous subtypes (phenotypes) has aided our clinical understanding. However, treatment options are limited for what still remains a challenging problem in clinical practice. Our evolving understanding of the diversity of asthma has led to seminal discoveries from the genetic revolution, recognising that genetic predisposition and environmental exposure (epigenetics) can influence the nature and course of the disease. This study aims to identify genetic and epigenetic markers associated with severe asthma and assess their function and clinical relevance. This will help to improve our understanding of severe asthma and may also reveal potential novel targets for future personalised treatments. We will invite participants from the following two established and extensively characterised cohorts to take part in the study. 1. The WATCH study (Wessex AsThma CoHort) has 350 enrolled participants with severe asthma from the Severe Asthma Clinic at University Hospital Southampton. 2. The Isle of Wight Whole Population Birth Cohort includes 130 current mild asthmatics at the David Hide Asthma and Allergy Centre, Isle of Wight. Sampling (blood, sputum and airway) will be undertaken over 2-3 visits, to provide material for genetic, epigenetic and immunological assessments which will be performed at the La Jolla Institute for Allergy and Immunology, San Diego,USA. Specialised DNA and RNA sequencing platforms will be used to identify genetic and epigenetic changes in immune cells driving the asthma process. We will also assess if oral steroids and the biological asthma treatments have any influence on the genetic and epigenetic changes that occur in severe asthma. In summary, this study will help to further develop our understanding of severe asthma at a molecular level.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
Lack of informed consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST and funded by National Institutes of Health (NIH), United States .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 39064
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
